Table 3.
DSM30011 Antimicrobial Susceptibility Phenotypes
| Method and Antimicrobials Tested | |||
|---|---|---|---|
| 1) Vitek-2 | MIC (µg/ml) |
||
| DSM30011 | ATCC17978 | ATCC19606 | |
| Ampicillin | 16 (R)a | 16 (R) | ≥32 (R) |
| Cefotaxime | 8 (S) | 8 (S) | 16 (R) |
| Ceftazidime | 4 (S) | 4 (S) | 16 (I) |
| Cefepime | 2 (S) | ≤1 (S) | 16 (I) |
| Imipenem | ≤0.25 (S) | ≤0.25 (S) | ≤0.25 (S) |
| Meropenem | ≤0.25 (S) | ≤0.25 (S) | 1 (S) |
| Amikacin | ≤2 (S) | ≤2 (S) | ≤2 (S) |
| Gentamicin | ≤1 (S) | ≤1 (S) | 8 (I) |
| Nalidixic acid | ≤2 (S) | 8 (S) | ≤2 (S) |
| Ciprofloxacin | ≤0.25 (S) | ≤0.25 (S) | 1 (S) |
| Nitrofurantoin | ≥512 (R) | ≥512 (R) | 256 (R) |
| Colistin | ≤0.5 (S) | ≤0.5 (S) | ≤0.5 (S) |
| Sulfamethoxazole/Trimetoprim (23.75/1.25) | ≤20 (S) | 160 (R) | ≥320 (R) |
| 2) Disk Diffusionb | Diameter Halo (mm) | ||
| Tetracyclin (30 µg) | 23 (S) | ||
| Azithromycin (15 µg) | 30 (n.s.c) | ||
| Erythromycin (15 µg) | 27 (n.s.) | ||
| Chloramphenicol (30 µg) | 15 (n.s.) | ||
a
Susceptibility interpretation (S: susceptible; R: resistant; I: intermediate) according to CLSI standards.
b
Tested only in DSM30011.
c
n.s.: not specified in the case of Acinetobacter spp., which are considered intrinsically resistant to these antibiotics. In the case of enterobacterial species such as Salmonella enterica serovar Typhi a 13 mm zone diameter for azithromycin (15 µg disk) is considered the limit separating susceptible from nonsusceptible isolates, and a 15 mm zone diameter for chloramphenicol (30 µg disk) corresponds to an isolate displaying intermediate resistance to this antibiotic.